Neuropeptides
PE-22-28
- 10 mg
Special order
Custom strengths on request
Not FDA-approved. Not on FDA's 503A category lists (May 14, 2026). Source, May 14, 2026
At a glance
These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.
No established human dose
Preclinical only. PE 22-28 (GVSWGLR) blocked TREK-1 in HEK cells (IC50 about 0.1 nM). In mice, acute intraperitoneal doses of 3.0-4.0 ug/kg reduced forced-swim immobility. That range covers the three spadin analogs together; PE 22-28 itself was given at 3.0 ug/kg in the corticosterone model. Four days of dosing raised hippocampal BrdU-positive cells. The only primary paper comes from the originating lab. There is no human study, no FDA label, and no clinician protocol with a traceable source, so no human dose can be cited. Mouse doses are per kg, depend on the route, and apply to the analog class. They are not human doses.
Get a quote
Custom strengths on request. Prices are quoted per clinic.